M
Marc Carrier
Researcher at Ottawa Hospital Research Institute
Publications - 396
Citations - 17092
Marc Carrier is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 58, co-authored 325 publications receiving 12428 citations. Previous affiliations of Marc Carrier include Ottawa Hospital & University of Ottawa.
Papers
More filters
Journal ArticleDOI
Perioperative Management of Dabigatran: A Prospective Cohort Study
Journal ArticleDOI
The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.
TL;DR: Hemodialysis with repeated exposure to unfractionated heparin was associated with a moderately elevated prevalence of PF4-H antibodies, but the results do not support a relationship between PF4,H antibodies and hemodialysis vascular access thrombosis.
Journal ArticleDOI
Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex
Marc Carrier,Marc A. Rodger,Dean Fergusson,Steven Doucette,Michael J. Kovacs,Jane C. Moore,John G. Kelton,Greg Knoll +7 more
TL;DR: The study suggests that IgG-specific PF4-H antibody formation is associated with increased mortality in hemodialysis patients.
Journal ArticleDOI
Clinical implications of incidental venous thromboembolism in cancer patients
Frits I. Mulder,Marcello Di Nisio,Cihan Ay,Marc Carrier,Floris T. M. Bosch,Annelise Segers,Noémie Kraaijpoel,Michael A. Grosso,George Zhang,Peter Verhamme,Tzu-Fei Wang,Jeffrey I. Weitz,Saskia Middeldorp,Gary E. Raskob,Ludo F. M. Beenen,Harry R. Büller,Nick van Es +16 more
TL;DR: Clinical adverse outcomes are substantial in both cancer patients with incidental and symptomatic VTE, supporting current guideline recommendations that suggest treating incidental VTE in the same manner as symptomatic venous thromboembolism.
Journal ArticleDOI
Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology.
Marc Carrier,Agnes Y.Y. Lee +1 more
TL;DR: Treatment with low-molecular weight heparin is the recommended first-line approach in cancer patients with newly diagnosed VTE, and is usually continued for a minimum of 3–6 months, and the impact of anticoagulants on survival is awaited.